Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Lasers Could Destroy Blood-borne Diseases

By Drug Discovery Trends Editor | November 1, 2007

Physicists in Arizona State University have designed a laser technique which can destroy viruses and bacteria such as AIDS without damaging human cells and may also help reduce the spread of hospital infections such as MRSA. The research, published  in the Institute of Physics’ Journal of Physics: Condensed Matter, discusses how pulses from an infrared laser can be fine-tuned to discriminate between problem microorganisms and human cells.

Current laser treatments such as UV are indiscriminate and can cause ageing of the skin, damage to the DNA or, at worst, skin cancer, and are far from 100 per cent effective. Femtosecond laser pulses, through a process called Impulsive Stimulated Raman Scattering (ISRS), produces lethal vibrations in the protein coat of microorganisms, thereby destroying them.  The effect of the vibrations is similar to that of high-pitched noise shattering glass.

The physicists in Arizona have undertaken experiments to show that the coherent vibrations excited by infrared lasers with carefully selected wavelengths and pulse widths do no damage to human cells, most likely because of the different structural compositions in the protein coats of human cells vis a vis bacteria and viruses.

Release date: October 31, 2007

Source: Institute of Physics


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50